Histamine and Cytokine Therapy: Paper presented at the annual meeting of the Swedish Oncology Society, Stockholm, 1997

References

• Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Im-munol Today 1992; 13: 265–70.
   Google Scholar
• Mellstedt H, Frodin JE, Ragnhammar P, et al. Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-IA) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF). Acta Oncol 1991; 30: 923–31.
   PubMed Web of Science ®Google Scholar
• Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993; 53: 5613–6.
   PubMed Web of Science ®Google Scholar
• Mizoguchi H, O'Shea JJ, Longo DL, et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992; 258: 1795–8.
   PubMed Web of Science ®Google Scholar
• Nakagomi H, Petersson M, Magnusson I, et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993; 53: 5610–2.
   PubMed Web of Science ®Google Scholar
• Kono K, Salazar-Onfray F, Petersson M, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-mod-ulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996; 26: 1308–13.
   PubMed Web of Science ®Google Scholar
• Matsuda M, Petersson M, Lenkei R, et al. Alterations in the signal-transducing molecules of T cells and NK cells in col-orectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int .1-Cancer 1995; 61: 765–72.
   PubMed Web of Science ®Google Scholar
• Kiessling R, Kono K, Petersson M, Wasserman K. Immuno-suppression in human tumor-host interaction: role of cytoki-nes and alterations in signal-transducing molecules. Springer Semin Immunopathol 1996; 18: 227–42.
   PubMed Web of Science ®Google Scholar
• Bottazzi B, Walter S, Govino D, Colotta F, Mantovani A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth and susceptibility to IL-2 therapy of a murine melanoma. J Immunol 1992; 148: 1280–5.
   Google Scholar
• Hellstrand K, Hermodsson S. Synergistic NK cell activation by histamine and interleukin-2. Int Arch Allergy Appl Im-munol 1990; 92: 379–89.
   PubMedGoogle Scholar
• Hellstrand K, Kylefjord H, Asea A, Hermodsson S. Regula-tion of the NK-cell response to IFN-a by biogenic amines. J Interferon Res 1992; 12: 199–206.
   PubMedGoogle Scholar
• Hellstrand K, Asea A, Dahlgren C, Hermodsson S. Histamin-ergic regulation of NK-cells: role of monocyte-derived, reac-tive oxygen metabolites. J Immunol 1994; 153: 4940–7.
   PubMed Web of Science ®Google Scholar
• Hansson M, Asea A, Ersson U, Hermodsson S, Hellstrand K. Induction of apoptosis in natural killer cells by monocyte-derived reactive oxygen metabolites. J Immunol 1996; 156: 42–7.
   Google Scholar
• Hellstrand K, Hermodsson S. Histamine H2 receptor medi-ated regulation of human natural killer cell cytotoxicity. J Immunol 1986; 137: 656–60.
   PubMed Web of Science ®Google Scholar
• Lynch NR, Salomon JC. Passive local anaphylaxis: demon-stration of antitumor activity and complementation of intra-tumor BCG. J Natl Cancer Inst 1977; 58: 1093–8.
   PubMed Web of Science ®Google Scholar
• Burtin C, Scheinmann P, Salomon JC, Lespinats G, Canu P. Decrease in tumour growth by injections of histamine or serotonin in fibrosarcoma-bearing mice: influence of HI and H2 histamine receptors. Br J Cancer 1982; 45: 54–60.
   Google Scholar
• Tatsuta M, Iishi H, Ichii M, Noguchi S, Yamamura H, Taniguchi H. Inhibitory effects of tetragastrin and histamine on carcinogenesis in the small intestines of W rats by N-methyl-N'-nitro-N-nitrosoguanidine. J Natl Cancer Inst 1986; 76: 277–81.
   PubMed Web of Science ®Google Scholar
• Suonio E, Tuomisto L, Alhava E. Effects of histamine, HI, H2 and H,c receptor antagonists and alpha-fluoromethylhis-tidine on the growth of human colorectal cancer in the subrenal capsule assay. Agents Actions 1994; 41: 118–20.
   Google Scholar
• dellaRovere F, Broccio G, Granata A, Fimiani V. In vivo experimental demonstration that hyperhistaminism counter-acts tumor growth. Oncol Reports 1994; 1: 175–7.
   PubMedGoogle Scholar
• Gifford RR, Ferguson RM, Voss BV. Cimetidine reduction of tumour formation in mice. Lancet 1981; 8221: 638–40.
   Google Scholar
• Gorczynski RM, Kennedy M, Ciampi A. Cimetidine reverses tumor growth enhancement of plasmacytoma tumors in mice demonstrating conditioned immunosuppression. J Immunol 1985; 134: 4261–6.
   Google Scholar
• Hellstrand K, Asea A, Hermodsson S. Role of histamine in natural killer cell mediated resistance against tumor cells. J Immunol 1990; 145: 4365–70.
   Google Scholar
• Caignard A, Martin M, Reisser D, Thomas B, Martin F. Effects of cimetidine and indomethacin on the growth of dimethylhydrazine-induced or transplanted intestinal cancers in the rat. Br J Cancer 1984; 50: 661–5.
   Google Scholar
• Anderson LM, Giner-Sorolla A, Haller IM, Budinger JM. Effects of cimetidine, nitrite, cimetidine plus nitrite, and nitro-socimetidine on tumors in mice following transplacental plus chronic lifetime exposure. Cancer Res 1985; 45: 3561–6.
   PubMed Web of Science ®Google Scholar
• Mandanas R, Schultz S, Scullin D, Einhorn LH. Phase II trial of cimetidine in metastatic melanoma. A Hoosier Oncology Group trial. Am J Clin Oncol 1991; 14: 397–9.
   PubMed Web of Science ®Google Scholar
• Creagan ET, Ahmann DL, Green SJ, et al. Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma. J Clin Oncol 1985; 3: 977–81.
   PubMed Web of Science ®Google Scholar
• Links M, Clingan PR, Phadke K, et al. A randomized trial of cimetidine with 5-fluorouracil and folinic acid in metastatic colorectal cancer. Eur J Surg Oncol. 1995; 21: 523–5.
   PubMedGoogle Scholar
• Wotherspoon HA, Anderson JR, Morran CG, McArdle CS. Randomized trial of an H2-receptor antagonist in gastric cancer. Br J Surg 1997; 84: 1168–9.
   PubMedGoogle Scholar
• Brunda MJ, Bellantoni D, Sulich V. In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 1987; 40: 365–441.
   Google Scholar
• Hellstrand K, Hermodsson S, Brune M, et al. Histamine in cancer immunotherapy. Scand J Clin Lab Invest 1997; 57: 193–202.
   PubMed Web of Science ®Google Scholar
• Asea A, Hermodsson S, Hellstrand K. Histaminergic regula-tion of natural killer-cell-mediated clearance of tumor cells in mice. Scand J Immunol 1996; 43: 9–15.
   Google Scholar
• Oldham RK, Blumenschein G, Schwartzberg L. Combination biotherapy utilizing interleukin-2 and a interferon in patients with advanced cancer: a National Biotherapy Study Group Trial. Mol Biother 1992; 4: 4–9.
   Google Scholar
• Hellstrand K, Naredi P, Lindner P, et al. Histamine in immunotherapy of advanced melanoma. A pilot study. Can-cer Immunol Immunother 1994; 39: 416–9.
   PubMed Web of Science ®Google Scholar
• Swansbury GJ, Lawler SD, Alimena G, et al. Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1994; 73: 1–7.
   PubMed Web of Science ®Google Scholar
• Thalhammer F, Geissler K, Jager U, et al. Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann Hematol 1996; 72: 216–22.
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Mellqvist UH, Wallhult E, et al. Histamine and interleukin-2 in acute myelogenous leukemia. Leuk Lymphoma 1997 (in press).
   Google Scholar
• Shepherd JD, Jacky E, Grathwohl A, et al. Phase II study of subcutaneous rHu IL-2 in patients with acute myelogenous leukemia in partial or complete second remission and partial relapse. Br J Haematol 1994; S87: 205.
   Google Scholar
• Bergmann L, Heil G, Kolbe K, et al. Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. Leuk Lymphoma 1995; 16: 271 —9.
   PubMedGoogle Scholar
• Brune M, Hellstrand K. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukemia. Br J Haematol 1996; 92: 620–6.
   PubMed Web of Science ®Google Scholar
• Brune M, Hansson M, Mellqvist UH, Hermodsson S, Hell-strand K. NK-cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur J Haematol 1996; 57: 312–9.
   Google Scholar